Reportstack

Monoclonal Antibodies Partnering Terms and Agreements

 
Repost This

Naperville, IL -- (SBWIRE) -- 02/19/2014 -- Reportstack, provider of premium market research reports announces the addition of Monoclonal Antibodies Partnering Terms and Agreements market report to its offering
The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

This report provides details of the latest monoclonal antibody deals announced in the healthcare sectors.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

                                

This report contains a comprehensive listing of all monoclonal antibody partnering deals announced since 2009 including financial terms where available including over 700 links to online deal records of actual biomarker partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

For example, analyzing actual company deals and agreements allows assessment of the following:

 

What is actually granted by the agreement to the partner company?

                

What exclusivity is granted?

 

What are the precise rights granted or optioned?

 

What is the payment structure for the deal?

 

How aresalesand payments audited?

 

What is the deal term?

 

How are the key terms of the agreement defined?

 

How are IPRs handled and owned?

 

Who is responsible for commercialization?

 

Who is responsible for development, supply, and manufacture?

 

How is confidentiality and publication managed?

 

How are disputes to be resolved?

 

Under what conditions can the deal be terminated?

 

What happens when there is a change of ownership?

 

What sublicensing and subcontracting provisions have been agreed?

 

Which boilerplate clauses does the company insist upon?

 

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

 

Which jurisdiction does the company insist upon for agreement law?

 

 

 

The initial chapters of this report provide an orientation of monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in monoclonal antibody dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

                    

Chapter 3 provides a review of the leading monoclonal antibody deals since 2009. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

                            

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of monoclonal antibody deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 5 provides a comprehensive listing of the top big biotech companies with a brief summary followed by a comprehensive listing of monoclonal antibody deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

 

Chapter 6 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since January 2009, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record, providing easy access to each contract document on demand.

 

Chapter 7 provides a comprehensive list and detailed review of monoclonal antibody partnering deals signed and announced since January 2009, by specific technology type. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

In addition, a comprehensive appendix is provided organized by monoclonal antibody partnering company A-Z, deal type, stage of development and therapy type deals. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of biomarker technologies and products.

 

 Report scope

                          

Monoclonal Antibodies Partnering Terms & Agreements is intended to provide the reader with an in-depth understanding and access to monoclonal antibodies trends and structure of deals entered into by leading companies worldwide.

 

                                            

Monoclonal Antibodies Partnering Terms & Agreements includes:

                                                        

Trends in monoclonal antibodies dealmaking in the biopharma industry since 2009

Analysis of monoclonal antibodies deal structure

Access to headline, upfront, milestone and royalty data

Access to over 500 monoclonal antibodies deal records

The leading monoclonal antibodies deals by value since 2009

Includes chimeric mAb, humanized mAb, human mAb and murine mAb deals and alliances since 2009

 

 In Monoclonal AntibodiesPartnering Terms & Agreements, the available deals are listed by:

 

Company A-Z

Headline value

Stage of development at signing

Deal component type

Monoclonal antibodies type

 

Monoclonal Antibodies Partnering Terms & Agreements provides the reader with the following key benefits:

 

In-depth understanding of monoclonal antibodies deal trends since 2009

Access to headline, upfront, milestone and royalty data

Acces to the structure of monoclonal antibodies agreements with numerous real life case studies

Comprehensive access to over 500 actual monoclonal antibodies deals entered into by the world’s biopharma companies

Insight into the terms included in a monoclonal antibodies agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals          

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

To view the table of contents for this market research report please visit
http://www.reportstack.com/product/150569/monoclonal-antibodies-partnering-terms-and-agreements.html
Contact:
Roger Campbell
contactus@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604
###